OriCell Therapeutics
Founded in 2015, OriCell Therapeutics aims to develop drugs with good efficacy and affordable prices to satisfy the globally unmet clinical needs through innovations and strives to become the world-leading developer of novel drugs for tumor immunotherapy. Oricell has raised over $120 million USD in series B financing in July 2022.
OriCell Therapeutics has made a large investment in the construction of synergistic innovative product R&D technology platforms. Its long-term development strategy is to focus on the global unmet clinical needs for the treatment of liver cancer, ovarian cancer, gastric cancer, cervical cancer, and non-small cell lung cancer, and develop innovative cellular drugs and bispecific antibodies with high clinical values. Adhering to the vision of "becoming the world-leading developer of novel drugs for tumor immunotherapy", OriCell Therapeutics will continue to explore and make efforts to provide patients and doctors with safer and more effective tumor treatment solutions, and help patients "restore health and reset vitality".
Focus on the development of independent innovation product pipelines
-
At present, 10 independent innovation pipelines for cellular drugs and bispecific antibodies targeting solid tumors have been established. Six products for tumor immunotherapy have entered the stage of clinical development, and two core IND applications are currently underway.
-
We have reached a global development agreement with ANTENGENE (B.6996) regarding our independently developed bispecific antibody, which is worth 142 million USD. Presently, the program has received approvals and is under way in Australia, the U.S. and China for phase I clinical trial.
-
The first CAR-T product developed by the company, targeting GPC-3 received positive data from an exploratory clinical study, which was presented at ASCO 2021. The product then received IND approval from NMPA in September 2022.
-
Our proprietary CAR-T cell therapy targeting GPRC5D (OriCAR-017) for the treatment of Relapsed/Refractory Multiple Myeloma (R/R MM) reported in oral presentation at ASCO 2022 annual meeting and the product has received orphan drug designation by US FDA. Its follow-up data was published on Lancet Haematology in Janurary 2023.
Qualifications and Honors
With a strong scientific innovation atmosphere and a team winning numerous awards, we are widely recognized.
- One of the accredited High- and New-Technology Enterprise in China
- One of the accredited National Technology-based Enterprise in China
- Co-construction unit of Shanghai Cell Therapy Clinical Transformation Engineering Technology Center
- The site for Shanghai Academician (Expert) Workstation
- The site for the Pudong New Area Enterprise Postdoctoral Research Workstation Substation
- Responsible unit for the biomedical technology support special project under the "Science and Technology Innovation Action Plan" of the Science and Technology Commission of Shanghai Municipality in 2019 and 2021
- One of the funded key technology start-up enterprises in Pudong New Area in 2019
- One of the Shanghai Science and Technology Innovation Companies in 2020
- Responsible unit for the technology innovation funding project for small and medium-sized technology-based enterprises under the "Science and Technology Innovation Action Plan" of the Science and Technology Commission of Shanghai Municipality in 2020 and 2021
- Won the first prize in the 13th "Zhangjiang Pharma Valley Cup" Biomedicine Experimental Skill Competition in 2020
- 2021 10th China Innovation & Entrepreneurship Competition Biopharmaceutical Group "Outstanding Business" Award
- 2021 Yangtze River Delta Innovative Women Entrepreneurs Gold Reward
- 2021 Shanghai High-technology Certified Business
- 2022 Shanghai Skill Master Studio Fund Sponsored Enterprises
- 2022 Zhangjiang Science City Digital Transformation Special Funding for Pharmaceutical R&D and Production Enterprises Sponsored Enterprises
- Having several team members who have gained honorary titles such as Shanghai Chief Technician, Science and Technology Talent of Pudong New Area, and Outstanding Technologist of the 30th Anniversary of Development and Opening of Pudong New Area.
Pudong new area enterprise post-doctoral scientific research workstation
Experts workstation
Shanghai cell therapy clinical engineering technology research
High Tech Business Certification
